CTRI/2019/04/018782招募中未知
Acute Myeloid Leukemia: Exploring the feasibility of multimodal-omics based genomic characterization, mrd evaluation and computational drug modelling to inform disease management (Altitude)
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- Tata Trusts
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Cytologically or histologically confirmed diagnosis of AML & MDS-EB2 (except acute promyelocytic leukemia and therapy related AML/MDS)
排除标准
- •Refractory AML and BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
研究者
相似试验
进行中（未招募）
不适用
Treatment for acute myeloid leukemia (AML) during its first complete remision with the monoclonal antibody Mylotarg ® (anti-CD33/calicheamicina) pre- and post- autologous transplant of hematopoietic stem cellsAcute myeloid leukemia (AML) during its first complete remision and with high relapse risk, pre- and post- autologous hematopoiteic transplantEUCTR2005-000640-91-ESInstitut de Recerca Hospital Sta. Creu i St. Pau20
已完成
不适用
Risk adapted treatment of Acute Myelocytic Leukaemia (AML)Acute Myeloid Leukaemia (AML)CancerISRCTN76815071Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)1,105
撤回
1 期
Tislelizumab with Azacitidine in the Treatment of R/R AMLRefractory AMLRelapsed Adult AMLNCT06586099Institute of Hematology & Blood Diseases Hospital, China
招募中
不适用
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in GreeceAcute Myeloid LeukemiaNCT05317494AbbVie100
招募中
不适用
Acute myeloid leukemia and myelodysplatic syndrome: parenteral-, enteral- and only oral nutrition during remission induction treatmentAcute myeloid leukemia and late stage myelodysplastic syndromeNL-OMON20839Maxima MC180